- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Scandion Oncology A/S: Scandion Oncology Announces Results of Annual General Meeting | 80 | GlobeNewswire (Europe) | The Annual General Meeting 2025 of Scandion Oncology A/S in liquidation (the "Company") was held on 27 March 2025 at 2:00 p.m.
All proposals were adopted in accordance with the notice.As such, the Company... ► Artikel lesen | |
| 13.03. | The observation status for Scandion Oncology A/S is updated | 121 | GlobeNewswire | On February 27, 2025, the shares and equity rights in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would... ► Artikel lesen | |
| 13.01. | Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer | 107 | GlobeNewswire (Europe) | Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II... ► Artikel lesen | |
| 30.08.24 | Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S | 443 | GlobeNewswire | As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser
to Vator Securities AB.
This information is distributed at the request of the Certified Adviser, Västra
Hamnen Corporate... ► Artikel lesen | |
| 18.07.24 | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 2 | 248 | GlobeNewswire | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 2
--------------------------------------
Short... ► Artikel lesen | |
| 18.07.24 | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 3 | 233 | GlobeNewswire | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 3
--------------------------------------
Short... ► Artikel lesen | |
| 11.07.24 | Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Scandion Oncology | 455 | GlobeNewswire | At the request of Scandion Oncology, the last trading day in Scandion
Oncology's paid subscription units will be changed from 2024-07-11 to
2024-07-15.
Instrument: Paid subscription units... ► Artikel lesen | |
| SCANDION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 04.06.24 | Nasdaq Stockholm AB: Listing of subscription units and paid subscription units of Scandion Oncology | 441 | GlobeNewswire | With effect from June 05, 2024, the subscription units in Scandion Oncology
will be traded on First North Growth Market. Trading will continue up until and
including June 17, 2024.
Instrument:... ► Artikel lesen | |
| 31.05.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.05.2024 | 436 | Xetra Newsboard | Das Instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024 The instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 23.05.24 | Scandion Oncology A/S: Scandion Oncology Announces The Final Terms Of The Rights Issue | 288 | GlobeNewswire (Europe) | On 19 April 2024, the board of directors of Scandion Oncology ("Scandion" or the "Company") resolved on the intention, subject to authorizations by the annual general meeting of the Company, to carry... ► Artikel lesen | |
| 22.05.24 | Scandion Oncology A/S: Scandion Oncology - Interim Report Q1 2024 | 185 | GlobeNewswire (Europe) | Scandion Oncology (Scandion) today announces its Interim Report Q1 2024. The following is taken from the report.
Francois Martelet, CEO:"Results from the CORIST Phase IIa trial have demonstrated impressive... ► Artikel lesen | |
| 13.05.24 | Scandion Oncology A/S: Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 | 320 | GlobeNewswire (Europe) | Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, today announces final data from the PANTAX... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
Das Unternehmen SCANDION ONCOLOGY A/S kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -81,48 % bei einem Aktienkurs von 0,001 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCANDION ONCOLOGY A/S finden Sie auf Wallstreet Online.
